Gemifloxacin (SB-265805) is a potent, novel fluoroquinolone with broad-spectrum antimicrobial activity. In this study, the efficacy of gemifloxacin was studied in experimental models of Gram-negative pyelonephritis (caused by Escherichia coli or Proteus mirabilis) and Grampositive wound infection resulting from Streptococcus pyogenes, Staphylococcus epidermidis or Staphylococcus aureus. Gemifloxacin activity against these pathogens was compared with those of amoxycillin-clavulanate, ciprofloxacin, cefuroxime, azithromycin, trovafloxacin, grepafloxacin, levofloxacin and tosufloxacin. Oral treatment was initiated 1 h after infection and continued once or twice daily for 3 days. Around 17 h after the end of treatment, animals were killed and the infected kidneys or the skin around the wound site were excised for the enumeration of viable bacteria. In the pyelonephritis model (either microorganism), gemifloxacin reduced bacterial numbers significantly (P < 0.01) compared with no treatment. No comparator agent had a greater effect than gemifloxacin. Notably, grepafloxacin and azithromycin were significantly less effective (P < 0.01) than gemifloxacin against E. coli pyelonephritis, and amoxycillin-clavulanate, azithromycin and trovafloxacin were inferior (P < 0.01) against P. mirabilis infection. In the S. pyogenes wound infection model, gemifloxacin, amoxycillin-clavulanate, cefuroxime and azithromycin reduced bacterial numbers significantly compared with controls (P < 0.01). Results for the comparator quinolones were not significantly different from untreated controls (P > 0.05). Gemifloxacin was also effective against staphylococcal infection, as were grepafloxacin and levofloxacin, while ciprofloxacin, trovafloxacin and tosufloxacin were significantly less effective against these pathogens than gemifloxacin (P < 0.01). No comparator agent had greater activity than gemifloxacin against S. pyogenes or S. aureus infections. These data demonstrate the potential benefit of gemifloxacin in the treatment of Gram-negative urinary tract infection and Gram-positive skin and soft tissue infection. 
Introduction
As resistance to the -lactams and macrolides has become more prevalent, quinolones have emerged as an alternative for therapy of infections in the community. Recently, a number of quinolone derivatives with enhanced potency against Gram-positive pathogens have become available for clinical or investigational use.
Gemifloxacin is a novel quinolone currently under development for the treatment of community-acquired infection. It displays broad-spectrum antibacterial activity against both Gram-positive and Gram-negative pathogens, 1 including strains resistant to other classes of agent.
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In vitro comparative studies of Gram-positive cocci have shown that gemifloxacin is active against Streptococcus pyogenes (MIC 90 0.06 mg/L) and against methicillinsusceptible (MIC 90 0.03 mg/L) and methicillin-resistant (MIC 90 2.0 mg/L) strains of Staphylococcus epidermidis and Staphylococcus aureus. This potency was equivalent or superior to that of a range of quinolone comparators. 6, 7 A study of recent clinical isolates has also found that gemifloxacin has equivalent or superior potency to comparator quinolones against the Gram-negative pathogens Escherichia coli (MIC 90 1.0 mg/L) and Proteus mirabilis (MIC 90 0.12 mg/L). 7, 8 Gram-negative bacteria are the most common pathogens in acute urinary tract infection. E. coli accounts for around 80% of community-acquired infections, while
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Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection
Valerie Berry*, Roni Page, Jennifer Satterfield, Christine Singley, Rob Straub and Gary Woodnutt [9] [10] [11] Gram-positive pathogens play an important role in skin and soft tissue infection, with S. aureus being of major aetiological importance, though S. epidermidis and S. pyogenes are also considered important pathogens. Infections of the urinary tract and skin and soft tissue are traditionally managed with oral antimicrobial agents in the outpatient setting. However, the clinical efficacy of drugs commonly used in such indications is being increasingly limited by the spread of bacterial resistance. [12] [13] [14] [15] When evaluating the potential clinical utility of an antimicrobial agent, MIC values and therapeutic efficacy cannot necessarily be correlated directly. 16 Pharmacokinetic parameters play an important role in clinical efficacy, and therefore discrepancies may be observed between in vitro activity and in vivo cure rate. 17, 18 Consequently, animal models form an important link between in vitro susceptibility findings and anticipated clinical results, and are a valuable source of reliable, qualitative information regarding the efficacy of new therapeutic agents.
The aim of this study was to investigate the efficacy of gemifloxacin against a broad spectrum of bacterial pathogens. To demonstrate this, gemifloxacin was tested in a rat model of pyelonephritis caused by E. coli or P. mirabilis, and a rat model of wound infection in which S. aureus, S. epidermidis or S. pyogenes was the aetiological agent. Comparator agents were amoxycillin-clavulanate, cefuroxime, azithromycin, ciprofloxacin, grepafloxacin, levofloxacin, trovafloxacin and tosufloxacin.
Materials and methods
Animals
Specific pathogen-free male Sprague-Dawley CD rats (Charles River, Raleigh, NC, USA) were used for both experimental models. Each treatment group comprised six animals. All procedures were performed in accordance with protocols approved by the SB Institutional Animal Care and Use Committee, and met or exceeded the standards of the American Association for the Accreditation of Laboratory Animal Care, the United States Department of Health and Human Services, and all local and federal animal welfare laws.
Bacterial strains
The strains used to initiate pyelonephritis were E. coli UTI17 and P. mirabilis C889, while the wound infection model used S. aureus WCUH29 (penicillin-resistant, MIC 64 mg/L; oxacillin-resistant, MIC 8.0 mg/L), S. epidermidis CL17 (penicillin-resistant, MIC 2.0 mg/L; oxacillin-resistant, MIC 8.0 mg/L) and S. pyogenes 257 (ciprofloxacinresistant MIC 2.0 mg/L) as the infecting strains. All bacterial isolates were chosen for their proven ability to produce infection in animal models, and for their antimicrobial susceptibility profiles (Table I) Tokyo, Japan), cefuroxime (Ceftin; Glaxo-Wellcome) and azithromycin (Zithromax; Pfizer) were used as commercial preparations. The compounds were prepared in phosphatebuffered saline (PBS). Gemifloxacin was administered as the mesylate salt and all other antimicrobials were used as pure free-acid equivalents.
Initiation of pyelonephritis
E. coli UTI17 and P. mirabilis C889 were grown overnight in trypticase soy broth (BBL, Becton Dickinson & Co., Cockeysville, MD, USA). Overnight cultures were centrifuged and resuspended in PBS to give inocula of approximately 9.4 log 10 cfu/mL for E. coli and 9.3 log 10 cfu/mL for P. mirabilis. Infection was then established using a method similar to that of Burrous & Cawein. 20 Briefly, animals (125-150 g) were anaesthetized with 3% isoflurane (Aerrane; Fort Dodge Animal Health, IO, USA) plus 1 L/min O 2 . Infection was then established by direct intrarenal injection into the left kidney with a 100 L inoculum containing approximately 8.4 log 10 cfu/rat for E. coli and 8.3 log 10 cfu/rat for P. mirabilis.
Initiation of wound infection
S. aureus WCUH29, S. epidermidis CL17 and S. pyogenes 257 were grown overnight in trypticase soy broth or ToddHewitt broth (Difco Laboratories, Detroit, MI, USA). Sterile suture threads (4/0 gauge, Surgisilk; Sutures Ltd, Ruabon, Clwyd, UK) were soaked in overnight broth culture for approximately 30 min before surgery. Animals (80-105 g) were anaesthetized by intraperitoneal injection (0.15 mL/100 g) of 100 mg/mL ketamine (Ketaset; Fort Dodge Animal Health, IO, USA) and 20 mg/mL xylazine (Rompun; Bayer Corporation, Shawnee Mission, KA, USA) and prepared for surgery. A 2 cm dorsal incision was made to the depth of the fascia, and a single infected suture was implanted into the connective tissue at the base of the incision. The suture was secured at each end and the wound closed with a skin staple. Mean bacterial numbers for sutures infected with S. pyogenes 257, S. aureus WCUH29 and S. epidermidis CL17 were 3.2, 6.9 and 6.8 log 10 cfu/ suture, respectively. This procedure results in a local abscess.
Antimicrobial therapy
Antimicrobial doses were chosen to approximate, in the rat, the serum or tissue AUCs (for azithromycin) following therapeutic dosing in humans, based upon total concentrations irrespective of serum binding (Table II) . [21] [22] [23] [24] [25] [26] [27] [28] [29] Antimicrobial agents were administered orally by gavage, in a volume of 6.7 mL/kg in the pyelonephritis model and 5 mL/kg for the wound infection model, commencing 1 h after infection, and therapy was continued once or twice daily for 3 days. For each study a further group of rats received water and served as untreated controls.
Efficacy evaluation
Approximately 17 h after the end of treatment, animals were killed by CO 2 overdose. In the pyelonephritis model both kidneys were excised, weighed and homogenized in 1 mL PBS to enable the recovery and enumeration of viable bacteria. Samples were inoculated (20 L) in triplicate on to cystine-lactose electrolyte-deficient agar plates (BBL) using a modified Miles-Misra technique. Colonies were counted following overnight incubation at 37°C. The lower limit of detection was 1.7 log 10 cfu/kidneys.
In the wound infection model, the skin section surrounding the wound was excised aseptically and homogenized in 1 mL PBS using a Seward stomacher (Brinkmann Instrument Inc., West Bury, NY, USA). Ten-fold serial dilutions were prepared in PBS for the enumeration of viable bacteria. Samples were inoculated (20 L) in triplicate using a modified Miles-Misra technique on to either nutrient agar plates (BBL) containing 5% defibrinated horse blood (S. pyogenes) or cystine-lactose electrolyte-deficient agar plates (Staphylococcus spp.). Colonies were counted after overnight incubation at 37°C and the lower limit of detection was 1.7 log 10 cfu/wound.
Data handling and analysis
For efficacy, the outcome measure for comparison of treatments was the number of bacteria in the kidneys (pyelonephritis model) or wound section (wound infection model) at the end of the study. All results are presented as group means with standard deviations. Statistical analysis was performed using Student's t test. P values of р0.05 were considered significant. Table I 
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Results
Pyelonephritis model
Following infection with E. coli UTI17, bacterial numbers in the kidneys of infected control animals were 5.5 Ϯ 0.42 log 10 cfu/kidneys (Figure 1a) , with evidence of infection in both kidneys generally being apparent 96 h after infection. All treated animals demonstrated significant therapeutic effects compared with untreated animals (P Ͻ 0.01). Gemifloxacin produced a potent response, reducing bacterial numbers to 1.8 Ϯ 0.1 log 10 cfu/kidneys. Similar effects were obtained with amoxycillin-clavulanate, ciprofloxacin, cefuroxime, levofloxacin, trovafloxacin and tosufloxacin (2.54 Ϯ 1.1, 1.7 Ϯ 0.08, 2.8 Ϯ 1.8, р1.7, 1.9 Ϯ 0.6 and 2.0 Ϯ 0.6 log 10 cfu/kidneys, respectively; P Ͼ 0.05 compared with gemifloxacin). However, gemifloxacin demonstrated superior activity compared with grepafloxacin and azithromycin (2.6 Ϯ 0.8 and 4.0 Ϯ 1.3 log 10 cfu/kidneys, respectively; P Ͻ 0.01). The number of bacteria isolated from the kidneys of control animals infected with P. mirabilis C889 (5.0 Ϯ 0.7 log 10 cfu/kidneys) was significantly higher (P Ͻ 0.01) than those obtained from treated animals (Figure 1b) . Although there was evidence of infection in the right kidney this was generally much less pronounced than in the left kidney, the point of bacterial inoculation. Gemifloxacin was highly efficacious, reducing bacterial numbers to the limit of detection in all animals (р1.7 log 10 cfu/kidneys). The activities of ciprofloxacin, cefuroxime, grepafloxacin, levofloxacin and tosufloxacin (which reduced bacterial numbers to р1.7, 2.4 Ϯ 1.0, 2.3 Ϯ 0.9, 1.8 Ϯ 0.2 and 1.8 Ϯ 0.3 log 10 cfu/kidneys, respectively) were similar to that of gemifloxacin (P Ͼ 0.05). In contrast, amoxycillin-clavulanate, azithromycin and trovafloxacin (which reduced bacterial numbers to 2.7 Ϯ 0.9, 4.0 Ϯ 0.6 and 2.7 Ϯ 1.1 log 10 cfu/kidneys, respectively) were significantly less effective than gemifloxacin (P Ͻ 0.01).
Wound infection model
Following infection with S. aureus WCUH29, mean bacterial numbers in untreated controls (6.8 Ϯ 0.1 log 10 cfu/ wound) were significantly higher than those recovered from all treatment groups (Figure 2a ). An approximately 3 log reduction in bacterial numbers was obtained following administration of gemifloxacin (3.51 Ϯ 0.85 log 10 cfu/ wound), similar to the effect recorded with grepafloxacin and levofloxacin (4.11 Ϯ 1.44 and 3.21 Ϯ 0.92 log 10 cfu/ wound, respectively, P Ͼ 0.05). Gemifloxacin was significantly (P Ͻ 0.01) more active than ciprofloxacin and trovafloxacin (which reduced bacterial numbers to 4.79 Ϯ 053 and 4.92 Ϯ 0.61 log 10 cfu/wound, respectively). Amoxycillin-clavulanate, cefuroxime, azithromycin and tosufloxacin had slight but statistically significant effects compared with control animals (reducing bacterial numbers to 6.36 Ϯ 0.18, 6.14 Ϯ 0.29, 6.18 Ϯ 0.51 and 6.32 Ϯ 0.40 log 10 cfu/wound, respectively; P Ͻ 0.01), but were less effective than gemifloxacin (P Ͻ 0.01).
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Gemifloxacin and levofloxacin were highly active against S. epidermidis CL17 infection, reducing bacterial numbers by approximately 2.5 log compared with untreated controls (3.48 Ϯ 0.72, 3.43 Ϯ 0.54 and 5.82 Ϯ 0.28 log 10 cfu/wound, respectively; P Ͻ 0.01) (Figure 2b) . Ciprofloxacin, grepafloxacin and trovafloxacin had a small but significant effect on bacterial numbers (reducing them to 4.6 Ϯ 0.47, 5.35 Ϯ 0.34 and 5.02 Ϯ 0.63 log 10 cfu/wound, respectively; P Ͻ 0.01), but had a lower efficacy than gemifloxacin (P Ͻ 0.01). Amoxycillin-clavulanate, cefuroxime, azithromycin and tosufloxacin elicited poor responses, and bacterial numbers were similar to those in controls (5.53 Ϯ 0.32, 5.43 Ϯ 0.52, 5.59 Ϯ 0.46 and 5.51 Ϯ 0.51 log 10 cfu/wound, respectively; P Ͼ 0.05).
Following infection with S. pyogenes 257, gemifloxacin demonstrated significant potency compared with untreated controls (reducing bacterial numbers to 3.22 Ϯ 1.62 compared with 6.5 Ϯ 0.4 log 10 cfu/wound; P Ͻ 0.01) ( Figure  2c ). Amoxycillin-clavulanate and cefuroxime were also highly active, reducing the bacterial count to below detectable limits (р1.7 log 10 cfu/wound; P Ͻ 0.01), while a Ͼ3 log reduction was seen with azithromycin compared with controls (3.06 log 10 cfu/wound; P Ͻ 0.01). Gemifloxacin was more effective (P р 0.01) than ciprofloxacin, grepafloxacin, levofloxacin, trovafloxacin and tosufloxacin, which yielded bacterial numbers equivalent to those in untreated controls (6.35 Ϯ 0.58, 6.15 Ϯ 0.35, 6.22 Ϯ 0.39, 5.56 Ϯ 1.94 and 6.14 Ϯ 0.42 log 10 cfu/wound, respectively; P Ͼ 0.05).
Discussion
In an experimental model of pyelonephritis, gemifloxacin demonstrated potent activity against E. coli and P. mirabilis infection. While all other treatment groups produced a significant response compared with untreated controls, the efficacy of gemifloxacin was superior to that of grepafloxacin and azithromycin against E. coli pyelonephritis. Against P. mirabilis pyelonephritis, all treatment groups again produced a significant therapeutic effect compared with untreated controls, though gemifloxacin was highly efficacious and reduced the bacterial count to the limit of detection. Its activity was significantly superior to that of amoxycillin-clavulanate, trovafloxacin and azithromycin. Previous studies have reported cephalosporins to be highly active in the treatment of experimental chronic pyelonephritis. 30 In this model, cefuroxime demonstrated a high level of activity against E. coli and P. mirabilis infection that was equivalent to that of gemifloxacin.
Investigators have reported that antimicrobial therapy in pyelonephritis must be initiated within 72-96 h of infection to allow any significant inhibition of renal scarring. 31, 32 However, the rate of acquisition of bacteria and the total number of bacteria in the kidney up to 96 h after infection are also important factors in the development of scarring. Prompt treatment with highly active antimicrobial agents offers the means to prevent the rapid expansion of bacterial numbers in the kidney, which is the stimulus to initiate the inflammatory response. The development of renal scarring may thus be prevented or significantly reduced.
The findings obtained in this rat model of wound infection reflect the in vitro potency of gemifloxacin against S. pyogenes, S. epidermidis and S. aureus and indicate that gemifloxacin may be useful for the treatment of infections caused by these Gram-positive organisms. In vitro studies have also found gemifloxacin to be moderately potent against methicillin-resistant isolates of S. epidermidis and S. aureus. 6 The results from this experimental model of infection confirm these observations, with gemifloxacin demonstrating significantly greater activity against penicillin-resistant S. aureus than amoxycillin-clavulanate, ciprofloxacin, cefuroxime, azithromycin, trovafloxacin and tosufloxacin. Gemifloxacin also demonstrated greater efficacy against penicillin-resistant S. epidermidis infection than ciprofloxacin, grepafloxacin, trovafloxacin, tosufloxacin, amoxycillin-clavulanate, cefuroxime and azithromycin. Overall, gemifloxacin was the most effective agent tested in these studies of experimental wound infection and demonstrated the greatest reduction in mean bacterial numbers of any of the quinolones studied (Table III) .
Community-acquired pathogens are exhibiting increasing levels of antimicrobial resistance. Any antimicrobial agent used as empirical therapy must, therefore, offer activity against a broad spectrum of pathogens with various resistance profiles to ensure clinical success. Rapid antimicrobial action is also necessary if complications of infection are to be avoided. The potent activity of gemifloxacin observed in these experimental models demonstrates its potential utility in the treatment of Gram-negative and Gram-positive infections. 
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